Spyre Therapeutics, Inc. (SYRE) — Stock Score Summary

Spyre Therapeutics, Inc. (SYRE) has a MoatMap StockRank of 36/100 based on Quality (28/100), Value (23/100), and Momentum (72/100) factor scores. The current signal is HOLD. Spyre Therapeutics is a pre-revenue biotechnology company. It lacks the quality metrics (Q: 28), cash flows, and commercialized products required for our fund, and is highly vulnerable to rising outsourced manufacturing costs.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for inflammatory bowel disease (IBD). The company utilizes advanced biologics engineering to create antibody candidates with superior efficacy and extended half-lives. Spyre's competitive position is built on its rational combination therapies and a pipeline designed to challenge established biologics in the immunology market.

Key Financial Metrics

Price$76.44
Market Cap$6.3B
P/E (Forward)-25.89
Price/Book12.01
Return on Equity-31.1%
Return on Invested Capital-30.5%
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-76M

Spyre Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Spyre Therapeutics, Inc.’s (SYRE) StockRank?
MoatMap’s StockRank for Spyre Therapeutics, Inc. (SYRE) is 36/100, with a Hold signal. It is a composite of Quality (28), Value (23), and Momentum (72) factor ranks across MoatMap’s 19,000+ stock universe.
Does Spyre Therapeutics, Inc. have an economic moat?
Spyre Therapeutics, Inc. (SYRE) has a Quality factor score of 28/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Spyre Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Spyre Therapeutics, Inc. (SYRE) is Hold, based on a StockRank of 36/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Spyre Therapeutics, Inc. in?
Spyre Therapeutics, Inc. (SYRE) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksSYRE deep dive reportAI ChampionsHow we score stocksSense-check another stock